GlaxoSmithKline has paid more than $150 million to settle government charges that the company fraudulently inflated the price of drugs purchased by federal health-care programs, the U.S. Justice Department said on Tuesday.
The settlement stems from allegations that the company violated the U.S. False Claims Act in the sale and marketing of Zofran and Kytril, two nausea drugs prescribed to patients undergoing cancer treatment, the department said.
Chump change? Maybe, but of the amount paid by GlaxoSmithKline, $26 million will go to whistle-blowers who prompted the investigation and another $10 million will go to state governments.
http://www.thestreet.com/_tsclsii/stocks/biotech/10243470.html
No comments:
Post a Comment